CZ309247B6 - 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru - Google Patents

40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru Download PDF

Info

Publication number
CZ309247B6
CZ309247B6 CZ2019-248A CZ2019248A CZ309247B6 CZ 309247 B6 CZ309247 B6 CZ 309247B6 CZ 2019248 A CZ2019248 A CZ 2019248A CZ 309247 B6 CZ309247 B6 CZ 309247B6
Authority
CZ
Czechia
Prior art keywords
hydroxyethyl
rapamycin
treating
active ingredient
sole active
Prior art date
Application number
CZ2019-248A
Other languages
English (en)
Other versions
CZ2019248A3 (cs
Inventor
Heidi Lane
Terence O´Reilly
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ309247(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CZ2019248A3 publication Critical patent/CZ2019248A3/cs
Publication of CZ309247B6 publication Critical patent/CZ309247B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)

Abstract

Vynález se týká 40-O-(2-hydroxyethyl)rapamycinu pro použití při léčení solidního nádoru slinivky břišní jako jediné účinné látky. Výhodně je solidní nádor pokročilým solidním nádorem. Výhodně je 40-O-(2-hydroxyethyl)rapamycin podán v jednotkové dávkové formě pro orální podání obsahující 0,25 až 10 mg 40-O-(2-hydroxyethyl)rapamycinu společně s jedním nebo více farmaceuticky přijatelnými ředidly nebo nosiči.
CZ2019-248A 2001-02-19 2002-02-18 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru CZ309247B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds

Publications (2)

Publication Number Publication Date
CZ2019248A3 CZ2019248A3 (cs) 2004-01-14
CZ309247B6 true CZ309247B6 (cs) 2022-06-22

Family

ID=26245731

Family Applications (5)

Application Number Title Priority Date Filing Date
CZ2018211A CZ309178B6 (cs) 2001-02-19 2002-02-18 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
CZ2019-248A CZ309247B6 (cs) 2001-02-19 2002-02-18 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
CZ2005-91A CZ307637B6 (cs) 2001-02-19 2002-02-18 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení
CZ2010-473A CZ307940B6 (cs) 2001-02-19 2002-02-18 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
CZ20032209A CZ303611B6 (cs) 2001-02-19 2002-02-18 Farmaceutické prostredky s obsahem derivátu rapamycinu pro lécení solidních nádoru

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CZ2018211A CZ309178B6 (cs) 2001-02-19 2002-02-18 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení

Family Applications After (3)

Application Number Title Priority Date Filing Date
CZ2005-91A CZ307637B6 (cs) 2001-02-19 2002-02-18 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení
CZ2010-473A CZ307940B6 (cs) 2001-02-19 2002-02-18 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
CZ20032209A CZ303611B6 (cs) 2001-02-19 2002-02-18 Farmaceutické prostredky s obsahem derivátu rapamycinu pro lécení solidních nádoru

Country Status (27)

Country Link
US (10) US8410131B2 (cs)
EP (11) EP3143995B2 (cs)
JP (14) JP2004525899A (cs)
KR (3) KR100695846B1 (cs)
CN (5) CN1296043C (cs)
AU (1) AU2002250968C1 (cs)
BR (1) BR0207378A (cs)
CA (3) CA2438504C (cs)
CY (11) CY1116616T1 (cs)
CZ (5) CZ309178B6 (cs)
DK (6) DK3342411T3 (cs)
ES (8) ES2921798T3 (cs)
HK (2) HK1250018B (cs)
HU (1) HUP0303271A3 (cs)
IL (13) IL157425A0 (cs)
LT (9) LT3351246T (cs)
LU (3) LU92880I2 (cs)
MX (3) MXPA03007418A (cs)
NO (14) NO333105B1 (cs)
NZ (1) NZ527692A (cs)
PL (5) PL409579A1 (cs)
PT (7) PT2269603E (cs)
RU (8) RU2322981C2 (cs)
SI (6) SI2762140T1 (cs)
SK (5) SK288546B6 (cs)
TW (2) TWI334350B (cs)
WO (1) WO2002066019A2 (cs)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP3143995B2 (en) * 2001-02-19 2025-01-15 Novartis Pharma AG Rapamycin derivative for the treatment of lung cancer
CN100496485C (zh) * 2001-06-01 2009-06-10 惠氏公司 抗肿瘤组合
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
PL375493A1 (en) * 2002-07-30 2005-11-28 Zentaris Gmbh Use of alkyl phosphocholines in combination with antitumor medicaments
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
BR0314555A (pt) * 2002-10-11 2005-08-09 Dana Farber Cancer Inst Inc Derivados de epotilona para o tratamento de mieloma múltiplo
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1626714B1 (en) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
CN1882338A (zh) 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
ES2494915T3 (es) * 2004-02-23 2014-09-16 Novartis Ag P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
BRPI0508959A (pt) * 2004-03-23 2007-08-14 Astrazeneca Ab uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
US20060182771A1 (en) 2005-02-09 2006-08-17 Dor Philippe J Formulations for ocular treatment
UA96412C2 (ru) * 2005-03-07 2011-11-10 Робартс Рисерч Инститьют Применение комбинации вируса миксомы и рапамицина для лечения
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
RU2443418C2 (ru) * 2005-07-20 2012-02-27 Новартис Аг КОМБИНАЦИЯ ПИРИМИДИЛАМИНОБЕНЗАМИДА И ИНГИБИТОРА КИНАЗ mTOR
EP2662082A1 (en) 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
JP2009516671A (ja) 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
HUE037890T2 (hu) 2006-02-02 2018-09-28 Novartis Ag Sclerosis tuberosa kezelése
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
DK2481402T3 (en) * 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
WO2009022190A1 (en) * 2007-08-16 2009-02-19 Biocompatibles Uk Limited Delivery of drug combinations
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US20120040896A1 (en) * 2008-04-11 2012-02-16 The Regents Of The University Of Colorado Compositions, methods and uses for modulation of brca 1
RU2509774C2 (ru) * 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
JP6243345B2 (ja) * 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
DK2852418T3 (en) 2012-05-23 2018-07-16 Smith & Nephew Apparatus for wound care with negative pressure
RU2015106112A (ru) 2012-08-01 2016-09-20 СМИТ ЭНД НЕФЬЮ ПиЭлСи Раневая повязка
EP3406231B1 (en) 2012-08-01 2022-04-13 Smith & Nephew plc Wound dressing and method of treatment
JP6715598B2 (ja) 2013-03-15 2020-07-01 スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ 創傷ドレッシングおよび治療方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
CN111214658B (zh) * 2015-08-17 2022-01-11 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症患者的方法
AU2017232348A1 (en) * 2016-03-15 2018-09-06 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer
EP3548894B1 (en) 2016-12-02 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3644914A1 (en) 2017-06-30 2020-05-06 T J Smith & Nephew Limited Negative pressure wound therapy apparatus
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CR20230103A (es) 2018-05-01 2023-04-11 Revolution Medicines Inc Análogos de rapamicina ligados a c40, c28 y c32 como inhibidores de mtor
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
EP3898637B1 (en) 2018-12-18 2024-11-20 Novartis AG Rapamycin derivatives
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
BR112021022784A2 (pt) 2019-05-14 2022-03-22 Tyme Inc Composições e métodos para tratamento do câncer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4417205A1 (en) 2021-10-14 2024-08-21 Pharos Ibio Co., Ltd Composition for combination therapy, comprising 2,3,5-substituted thiophene compound
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009010A1 (en) * 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
WO1997047317A1 (en) * 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (cs) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
AU5151093A (en) 1992-10-14 1994-05-09 Unichema Chemie Bv Process for the preparation of alkylglycosides
JP3398382B2 (ja) 1992-10-28 2003-04-21 ジェネンテク，インコーポレイテッド 血管内皮細胞増殖因子アンタゴニスト
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
AU2356195A (en) * 1994-04-14 1995-11-10 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
ES2249800T3 (es) 1996-06-24 2006-04-01 Pfizer Inc. Derivados triciclicos sustituidos con fenilamino para el tratamento de enfermedades hiperproliferativas.
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
CN1235608A (zh) 1996-09-09 1999-11-17 美国家用产品公司 烷基化的雷帕霉素衍生物
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
GB9619631D0 (en) 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
DE69918074T2 (de) 1998-03-26 2004-11-04 Fujisawa Pharmaceutical Co., Ltd. Makrolid-formulierung mit verzögerter wirkstoffabgabe
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
PL343627A1 (en) * 1998-04-27 2001-08-27 Fujisawa Pharmaceutical Co Medicinal compositions
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
CN1156480C (zh) 1999-08-18 2004-07-07 恵氏公司 水溶性sdz-rad酯，其制备方法和用途及其组合物
AU2292801A (en) 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
AU2623201A (en) * 1999-12-30 2001-07-16 Kam W Leong Controlled delivery of therapeutic agents by insertable medical devices
AU2001230956B2 (en) 2000-01-14 2005-08-18 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
WO2002022133A1 (en) * 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2002239436B2 (en) 2000-10-31 2007-04-26 Cook Medical Technologies Llc Coated implantable medical device
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
DE60130032D1 (de) * 2000-12-22 2007-09-27 Avantec Vascular Corp Vorrichtung zur Abgabe von therapeutischen Wirkstoffen
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
EP3143995B2 (en) * 2001-02-19 2025-01-15 Novartis Pharma AG Rapamycin derivative for the treatment of lung cancer
DE60228699D1 (de) * 2001-04-06 2008-10-16 Wyeth Corp Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
CN100496485C (zh) 2001-06-01 2009-06-10 惠氏公司 抗肿瘤组合
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
JP2009516671A (ja) 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
US9504809B2 (en) 2011-07-01 2016-11-29 Coloplast A/S Catheter with a balloon
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009010A1 (en) * 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
WO1997047317A1 (en) * 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. Grewe a kol.: „Regulation of Cell Growth and Cyclin D1 Expression by the Constitutively Active FRAP-p70S6K Pathway in Human Pancreatic Cancer Cells" Cancer Research 59, 3581-3587 (1999) *
M. Hidalgo a E. K. Rowinsky: „The rapamycin-sensitive signal transduction pathway as a target for cancer therapy" Oncogene 19, 6680-6686 (2000) *
M. Majewski a kol.: „The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders" Proc Natl Acad Sci USA 97 (8) 4285-90 (2000) *
S.A. Shah a kol.: „FRAP-p70s6K Signaling Is Required for Pacreatic Cancer Cell Proliferation". J. Surg Res. 97 (2) 123-30 (květen 2001) – prezentováno na Annual Meeting of the Association for Academic Surgery, Tampa, Florida, 2-4.11. 2000 *
T. Seufferlein a kol.: „Constitutive activation of p70s6k in human pancreatic cancer cell lines bearing activating Ki-ras mutations" Gastroenetrology 114 (4) abstrakt G2023 (1998) *

Also Published As

Publication number Publication date
LT3351246T (lt) 2019-07-10
NO20150895L (no) 2003-10-17
CA2860306A1 (en) 2002-08-29
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
ES2728739T3 (es) 2019-10-28
JP2014193901A (ja) 2014-10-09
CZ200591A3 (cs) 2019-01-23
JP2014208657A (ja) 2014-11-06
IL202155A0 (en) 2010-06-16
RU2322981C2 (ru) 2008-04-27
RU2018127821A (ru) 2020-01-30
LT2269604T (lt) 2016-11-10
IL229158A (en) 2017-03-30
EP2762140B1 (en) 2017-03-22
CY2019030I1 (el) 2020-05-29
CY1121715T1 (el) 2020-05-29
US20120283285A1 (en) 2012-11-08
EP2783686A8 (en) 2015-03-04
RU2006140514A (ru) 2008-05-27
IL229156A (en) 2017-02-28
IL220096A0 (en) 2012-07-31
JP2007284454A (ja) 2007-11-01
EP3342411A1 (en) 2018-07-04
NO20033651L (no) 2003-10-17
ES2921798T3 (es) 2022-08-31
US20160303092A1 (en) 2016-10-20
US8436010B2 (en) 2013-05-07
SK288545B6 (sk) 2018-03-05
JP6904640B2 (ja) 2021-07-21
JP2018100282A (ja) 2018-06-28
TW200626151A (en) 2006-08-01
HUP0303271A3 (en) 2010-09-28
SI3351246T1 (sl) 2019-08-30
IL229160A0 (en) 2013-12-31
RU2013143306A (ru) 2015-03-27
US20130059877A1 (en) 2013-03-07
PL363918A1 (pl) 2004-11-29
CN104274442A (zh) 2015-01-14
CA2860306C (en) 2018-04-17
NO336581B1 (no) 2015-09-28
NO20033651D0 (no) 2003-08-18
MX368013B (es) 2019-09-13
IL220096A (en) 2015-10-29
NO336428B1 (no) 2015-08-17
IL259724B (en) 2021-12-01
CY2016047I2 (el) 2017-04-05
JP6383814B2 (ja) 2018-08-29
US20040147541A1 (en) 2004-07-29
JP2016222705A (ja) 2016-12-28
EP1363627A2 (en) 2003-11-26
EP2269603B1 (en) 2015-05-20
CZ2019248A3 (cs) 2004-01-14
NO20120451L (no) 2003-10-17
CY1116616T1 (el) 2017-03-15
EP3406249A1 (en) 2018-11-28
RU2011138835A (ru) 2013-03-27
SI2269603T1 (sl) 2015-08-31
CZ2018211A3 (cs) 2004-01-14
NO336208B1 (no) 2015-06-15
CY2019030I2 (el) 2020-05-29
HK1197723A1 (en) 2015-02-13
NO340924B1 (no) 2017-07-17
DK3342411T3 (da) 2019-09-02
US20130244951A1 (en) 2013-09-19
PT3143995T (pt) 2019-01-17
PT3345602T (pt) 2022-07-04
EP3345602A1 (en) 2018-07-11
DK3351246T3 (da) 2019-06-03
BR0207378A (pt) 2004-06-15
SK288834B6 (sk) 2021-03-10
NO20131544L (no) 2003-10-17
EP3345602B1 (en) 2022-04-06
IL229158A0 (en) 2013-12-31
NO20131546L (no) 2003-10-17
NO20150831A1 (no) 2015-06-24
DK3143995T3 (en) 2019-01-28
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
HK1198946A1 (en) 2015-06-19
JP2020143134A (ja) 2020-09-10
LTPA2020503I1 (lt) 2020-03-10
CZ20032209A3 (cs) 2004-01-14
SI2762140T1 (sl) 2017-07-31
NO20170803A1 (no) 2003-10-17
RU2445093C2 (ru) 2012-03-20
EP2764865A2 (en) 2014-08-13
MXPA03007418A (es) 2003-11-18
CY1119029T1 (el) 2018-01-10
CY2016047I1 (el) 2017-04-05
IL229157A0 (en) 2013-12-31
JP6349476B2 (ja) 2018-06-27
PL414996A1 (pl) 2016-02-29
EP2783686A1 (en) 2014-10-01
IL220095A0 (en) 2012-07-31
PL409579A1 (pl) 2015-03-02
CZ2010473A3 (cs) 2004-01-14
RU2003127391A (ru) 2005-03-27
JP6333766B2 (ja) 2018-05-30
NO335134B1 (no) 2014-09-22
CA2994779A1 (en) 2002-08-29
JP6310970B2 (ja) 2018-04-11
US20130253000A1 (en) 2013-09-26
NO20190290A1 (no) 2003-10-17
LU92880I2 (fr) 2016-11-17
ES2543383T3 (es) 2015-08-18
CY2019043I1 (el) 2020-05-29
NO20161348A1 (no) 2016-08-24
PT2762140T (pt) 2017-07-04
SI3342411T1 (sl) 2019-10-30
PT3342411T (pt) 2019-09-19
JP5879391B2 (ja) 2016-03-08
CY2015044I2 (el) 2017-03-15
IL157425A (en) 2013-10-31
ES2744377T3 (es) 2020-02-24
DK2269603T3 (en) 2015-08-24
EP3143995B1 (en) 2018-12-05
PL415000A1 (pl) 2016-02-29
CA2438504A1 (en) 2002-08-29
CA2994779C (en) 2020-08-25
LTC2269604I2 (lt) 2020-01-27
PT3351246T (pt) 2019-06-07
WO2002066019A3 (en) 2002-10-24
IL251270A0 (en) 2017-06-29
LUC00122I1 (cs) 2019-06-06
DK2762140T3 (en) 2017-07-10
IL220095A (en) 2017-05-29
HK1146245A1 (en) 2011-05-27
RU2018121314A3 (cs) 2021-10-06
CY1121314T1 (el) 2020-05-29
CN1551767A (zh) 2004-12-01
HK1250018B (en) 2020-04-17
LT3342411T (lt) 2019-09-25
CY2015044I1 (el) 2017-03-15
CY1121983T1 (el) 2020-05-29
EP2764865A3 (en) 2014-10-01
NO20130045L (no) 2003-10-17
US20130296359A1 (en) 2013-11-07
JP2015145411A (ja) 2015-08-13
CZ309178B6 (cs) 2022-04-20
US8410131B2 (en) 2013-04-02
NO334646B1 (no) 2014-05-05
EP2269603A1 (en) 2011-01-05
ES2705016T3 (es) 2019-03-21
JP2017081979A (ja) 2017-05-18
JP2018168188A (ja) 2018-11-01
CN104116738A (zh) 2014-10-29
NO343599B1 (no) 2019-04-08
EP2269604B1 (en) 2016-07-27
RU2013119705A (ru) 2014-11-10
CY2020005I1 (el) 2020-05-29
EP2762140A1 (en) 2014-08-06
NO340553B1 (no) 2017-05-08
KR20050095906A (ko) 2005-10-04
JP6349475B2 (ja) 2018-06-27
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
LTPA2016035I1 (lt) 2016-12-27
CN1296043C (zh) 2007-01-24
RU2659725C2 (ru) 2018-07-03
CN1679559A (zh) 2005-10-12
ES2640787T3 (es) 2017-11-06
JP2004525899A (ja) 2004-08-26
HK1250019A1 (en) 2018-11-23
JP6349474B2 (ja) 2018-06-27
SK10382003A3 (sk) 2004-03-02
ES2600304T3 (es) 2017-02-08
NO20150413L (no) 2003-10-17
EP2783686B1 (en) 2017-06-21
SI3143995T1 (sl) 2019-02-28
PL414997A1 (pl) 2016-02-29
JP5873128B2 (ja) 2016-03-01
IL157425A0 (en) 2004-03-28
NO20131547L (no) 2003-10-17
KR20040007451A (ko) 2004-01-24
NO333105B1 (no) 2013-03-04
SK288546B6 (sk) 2018-03-05
EP3143995A1 (en) 2017-03-22
AU2002250968B2 (en) 2006-01-12
LU93320I2 (fr) 2017-01-30
JP5775022B2 (ja) 2015-09-09
PT2269603E (pt) 2015-09-09
DK2269604T3 (en) 2016-11-14
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
KR20070102762A (ko) 2007-10-19
HK1146247A1 (en) 2011-05-27
IL229156A0 (en) 2013-12-31
RU2005105664A (ru) 2006-08-10
SK288524B6 (sk) 2018-01-04
IL250676A0 (en) 2017-03-30
US20130287769A1 (en) 2013-10-31
TWI334350B (en) 2010-12-11
ES2629317T3 (es) 2017-08-08
IL251270B (en) 2018-06-28
MX2019010879A (es) 2019-12-16
CN104083365A (zh) 2014-10-08
LTPA2019511I1 (lt) 2019-06-25
PT2269604T (pt) 2016-11-04
US20140105895A1 (en) 2014-04-17
NO20131545L (no) 2003-10-17
JP2014177469A (ja) 2014-09-25
KR100695846B9 (ko) 2021-09-30
WO2002066019A2 (en) 2002-08-29
SK902019A3 (cs) 2004-03-02
EP3143995B2 (en) 2025-01-15
LUC00122I2 (cs) 2019-12-24
US8778962B2 (en) 2014-07-15
EP2269604A1 (en) 2011-01-05
US8877771B2 (en) 2014-11-04
CA2438504C (en) 2016-02-16
IL259724A (en) 2018-08-30
NO2015010I1 (no) 2015-03-30
JP2012184238A (ja) 2012-09-27
AU2002250968C1 (en) 2018-01-04
IL250676B (en) 2018-06-28
CY1118316T1 (el) 2017-04-05
KR100695846B1 (ko) 2007-03-19
PL231418B1 (pl) 2019-02-28
CZ307940B6 (cs) 2019-09-04
SI2269604T1 (sl) 2016-11-30
EP3342411B1 (en) 2019-08-21
LT2762140T (lt) 2017-06-26
US20120214774A1 (en) 2012-08-23
JP2018100283A (ja) 2018-06-28
IL229159A0 (en) 2013-12-31
NO336110B1 (no) 2015-05-18
CZ303611B6 (cs) 2013-01-09
JP2018100281A (ja) 2018-06-28
CZ307637B6 (cs) 2019-01-23
HK1250336B (en) 2020-02-07
IL229160B (en) 2018-08-30
SK288630B6 (sk) 2019-01-08
EP3351246B8 (en) 2019-09-18
IL202155A (en) 2013-04-30
HUP0303271A2 (hu) 2004-01-28
NZ527692A (en) 2005-05-27
LT3143995T (lt) 2019-01-25

Similar Documents

Publication Publication Date Title
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
EP1933833B8 (en) Therapy for the treatment of overactive bladder
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
GB0222514D0 (en) Organic compounds
AU3850600A (en) Dalda analogs and their use
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
SE9802208D0 (sv) Novel compounds
SE0102440D0 (sv) New compound
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
NO20013414D0 (no) Ny anvendelse av melagatran
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
SE9802209D0 (sv) Novel compounds
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
EA200600998A1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
MXPA05012826A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen.
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
BR0016654A (pt) Composto, método para o tratamento da dor, e, composição farmacêutica
EP1547596A4 (en) MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20220218

MK4A Patent expired

Effective date: 20220218

MK4A Patent expired

Effective date: 20220218